Introduction
Fosfomycin is a small molecule that inhibits the first step in peptidoglycan (cell wall) synthesis by acting as an analogue of phosphoenolpyruvate. This original antimicrobial agent, with a serum half-life of approximately 1.75 h, exhibits a broad spectrum of antimicrobial activity. 1 Fosfomycin is widely used in Europe, Japan and Latin America; in the USA (where it was developed), it never reached the market. It was the aim of this study to evaluate the in-vitro activity of fosfomycin against vancomycinresistant (VR) enterococci. VR enterococci, first reported in Europe in 1988, 2 are emerging as a global threat to public health. Alternatives to vancomycin are few due to the multiple drug resistance typical of VR Enterococcus faecium. To our knowledge, no data on the in-vitro activity of fosfomycin against VR enterococci have been published.
Materials and methods

Bacterial strains
One hundred and eighteen enterococcal strains (with and without different types of resistance to glycopeptides) of the following species were investigated for their in-vitro susceptibility to fosfomycin: E. faecium (VanA, n 69; VanB, n 5; glycopeptide-sensitive, n 8), Enterococcus faecalis (VanA, n 11; VanB, n 3; glycopeptide sensitive, n 10), Enterococcus gallinarum (VanC 1 , n 10), and Enterococcus casseliflavus (VanC 2 , n 2). Isolates originated from the strain collection of the Robert Koch Institute, Wernigerode, Germany.
Susceptibility testing
Minimal inhibitory concentrations (MICs) of fosfomycin were determined by agar dilution test (inoculum 5 10 4 cfu/spot) 3 and broth microdilution test (inoculum 5 10 5 cells/mL). 4 In all susceptibility test methods, MuellerHinton (MH) agar or broth were used as nutrient media (Oxoid, Basingstoke, UK). As recommended by the producer of fosfomycin (Sigma Chemical Co., St Louis, MO, USA), the liquid and the solid MH media were supplemented with -D-glucose-6-phosphate (Sigma; final conc e ntration 25 mg/L). An MIC of 128 mg/L characterizes a strain as resistant, 32-64 mg/L as intermediate, and
16 mg/L as susceptible. 5, 6 Isolates were also tested by the disc diffusion test (according to the NCCLS method 8 with a lighter inoculum resulting in a semiconfluent growth). For preparing the inocula the same cultures of the corresponding strains in nutrient broth were used in all four susceptibility tests. Oxoid discs loaded with fosfomycin (50 µg) plus -D-glucose-6-phosphate (50 µg) were used for disc susceptibility testing. Andrews et al. 6 proposed breakpoints for fosfomycin (corresponding to intravenous administration of 2 or 4 g), of 16 and 64 mg/L, corresponding to zone sizes (NCCLS method) of 11 and 18 mm, respectively. No official NCCLS zone sizes exist for fosfomycin. According to DIN 58940, zone diameters of 13 mm are read as resistant, and those of 20 mm as susceptible. 5 The recommended daily dosage of fosfomycin for severely ill patients is 8-16 g. 
Results
Summarized results of the agar dilution test are shown in Table I . By agar dilution, fosfomycin inhibited 97% of the VR strains and all vancomycin-susceptible (VS) isolates at concentrations 64 mg/L. The fosfomycin MICs for the four resistant E. faecium isolates were 256 mg/L. Summarized results from the disc diffusion test according to the DIN 58940 technique are presented in Table III . By this method, fosfomycin inhibited 96% of the VR strains (zone diameter 14 mm). The four VR E. faecium isolates showing fosfomycin resistance by agar dilution were also resistant by disc diffusion (DIN 58940): three strains gave inhibition zones of 6 mm diameter and one had a zone of 8 mm. One E. faecium isolate possessed an inhibition zone of 13 mm ( resistant) despite having fosfomycin MICs of 64 mg/L by the two dilution methods.
These three test methods showed good correlation for recognition of fosfomycin resistance. Major discrepancies were found between the two dilution methods and the disc diffusion (DIN 58940) method in discriminating fully susceptible from intermediately susceptible strains. Twenty of 100 VR enterococci (four of 18 VS) were determined to be fully susceptible to fosfomycin by the agar dilution method; 17 of 100 VR enterococci (seven of 18 VS) were found to be fully susceptible by the broth microdilution method. Disc diffusion (DIN 58940) found 68 of 100 VR enterococci (17 of 18 VS) to be fully susceptible to fosfomycin.
Inoculating plates for disc diffusion testing according to the NCCLS method, with the breakpoints stated by Andrews et al., 6 gave rates of resistance comparable with those of the other three methods (Table IV) . Of 74 VR E. faecium isolates, 6 were found to be fosfomycin resistant.
Finally, full resistance to fosfomycin could only be detected in VanA and VanB type E. faecium.
Discussion
Treating infections caused by VR enterococci presents major problems. Many of these strains are also highly resistant to aminoglycosides and other antimicrobial agents. Fortunately, most VR E. faecalis remain relatively susceptible to penicillin and ampicillin; thus standard principles of enterococcal infection therapy can be applied to these organisms. 10 Vancomycin-resistant E. faecium are often highly resistant to -lactams and combinations of other antimicrobials. For infections due to strains for which MICs of ampicillin are 64 mg/L, high-dose ampicillin may be tried, in combination with an aminoglycoside if there is no high-level resistance to the corresponding aminoglycoside. 10 A variety of other regimens have been utilized but there are no published data on the effectiveness of these regimens in humans. Teicoplanin has been used in cases of infection due to VR enterococci exhibiting the VanB phenotype. The investigational drugs quinupristin/dalfopristin, oxazolidinone, everninomycin, a new glycopeptide (LY 333328), and several fluoroquinolones including trovafloxacin and clinafloxacin with activity against VR enterococci are presently undergoing clinical evaluation. 10 Fosfomycin inhibited 97, 94 and 96% of the VR strains tested in our study by means of agar dilution, broth microdilution, and disc diffusion by DIN 58940, respectively. Using zone size diameters suggested by Andrews et al., 6 the disc diffusion test (according to the NCCLS method) gave susceptibility results concordant with those of the three other methods tested here. NCCLS criteria do not exist for disc diffusion testing of fosfomycin.
Recently Barry et al. 11 and Fuchs et al. 12 used NCCLS methods for testing susceptibility to fosfomycin tromethamine, a drug to be used for single-dose treatment of uncomplicated lower urinary tract infections, but they abstained from defining breakpoints for enterococci.
Hamilton-Miller 13 found that fosfomycin could be a useful addition to the limited number of antibiotics currently available that are effective against infections caused by problematic Gram-positive cocci but no detailed information on species results or glycopeptide susceptibility was given for the 20 enterococci tested in his study, 19 of which were found to be susceptible to fosfomycin (MIC range 15 reported that in an animal endocarditis study using a VR E. faecium strain (inhibited by fosfomycin plus ceftriaxone in vitro), most vegetations were sterilized. Landman & Quale 16 found that this combination showed bactericidal synergy against some VRE.
Screening for the -lactam with the strongest beneficial effect in combination with fosfomycin, Pestel et al. 17 showed that cefotaxime (at 64 mg/L) combined with fosfomycin (at 64 mg/L) was bactericidal against six of ten bloodstream isolates of VS enterococci tested. Studying the in-vivo activity of the combination of daptomycin and fosfomycin against a VS E. faecalis strain in a relapse model of rat endocarditis, Rice et al. 18 in contrast found that there was no difference between the number of valves sterilized by daptomycin alone and by daptomycin plus fosfomycin, despite synergic bactericidal activity found in in-vitro time-kill studies. In-vitro synergy does not necessarily translate into greater therapeutic efficacy against clinical infection.
In conclusion, the MICs of fosfomycin for most VR isolates were in the intermediate range, yielding an MIC 50 of 32 mg/L and an MIC 90 of 64 mg/L. The majority of zone sizes corresponded to intermediate susceptibility. Fosfomycin as a single agent at a low dosage therefore seems unsuitable for the treatment of infections due to VR enterococci. Fosfomycin at a high dosage could have a potential for the treatment of infections due to VR enterococci, especially if used in combination with other drugs. However, in-vitro activity does not guarantee invivo success. Until more effective agents are available, cure of some deep-seated infections due to VR enterococci may even require surgical intervention. 16 
